Evaxion Reports Q2 Losses
Evaxion Reports Q2 2026 Loss Despite AI-Immunology Pipeline Progress
Key Points
Notable institutional moves in Q2 2026 included multiple funds adjusting their EVAX positions: J. Safra Sarasin added 22,896 shares; Jane Street added 20,581; Citadel Advisors added 18,811; UBS Group added 6,275; while Renaissance Technologies reduced by 5,425 shares.
Analyst price targets in the past six months show a mixed near-term view, with a median target of $10.0 and at least one price target notably higher at $16.0 (HC Wainwright & Co.) while Jones Trading issued a $10 target.
The 6-K filing for Evaxion includes unaudited condensed consolidated interim financial statements for the six months ended June 30, 2026, covering comprehensive loss, balance sheet details, and changes in equity, as well as notes on warrants and related financing activities.
A conference call and webcast to discuss the results was scheduled for 8:30 ET / 14:30 CET on the release day, providing management commentary and Q&A for investors.
Evaxion A/S missed expectations in Q2 2026, reporting a loss of $0.50 per share against estimates of $0.32, while the Danish biotech reported zero revenue QuiverQuant. Despite the disappointing financials, the clinical-stage company emphasized progress across its AI-Immunology vaccine pipeline and extended its cash runway into the second half of 2027 TipRanks.
Evaxion highlighted milestone achievements across programs EVX-01, EVX-04, EVX-05, and EVX-V1, plus won the Prix Galien UK Award for Best digital health solution Business Insider. The company plans to present data at major conferences and held an investor call on August 20th to discuss results and strategy.
Larger Losses Than Wall Street Expected
Evaxion's Q2 loss of $0.50 per share came in $0.18 worse than the $0.32 estimate QuiverQuant. The company reported a net loss of $3.7 million for the quarter TipRanks. With zero revenue, the biotech is burning cash as it advances clinical-stage programs toward data readouts and regulatory milestones.
Cash Runway Extended Into Late 2027
Despite the loss, Evaxion extended its cash runway into the second half of 2027 TipRanks. The company filed a 6-K with the SEC containing unaudited condensed financial statements for the six months ended June 30, 2026, covering balance sheet details, equity changes, and warrant-related financing activities TipRanks. This runway gives management time to deliver on pipeline milestones.
Multiple Analysts Split on Near-Term Upside
Price targets from recent research show mixed sentiment. HC Wainwright & Co. set a $16.00 target, while Jones Trading issued a $10.00 target. The median target sits around $10.00, suggesting modest near-term gains from current levels TipRanks. Institutional investors have also adjusted positions, with J. Safra Sarasin adding 22,896 shares and Jane Street adding 20,581 shares in Q2 Quiver.
Pipeline Advances Despite Zero Current Revenue
Evaxion is developing novel vaccines using its AI-Immunology platform Business Insider. The company is advancing programs EVX-01, EVX-04, EVX-05, and EVX-V1 through clinical stages. It also won the Prix Galien UK Award for Best digital health solution, validating its technology approach Business Insider. Management plans to present data at major conferences, signaling confidence in upcoming readouts.
Sentiment
Mostly PositivePublishers
15
Articles
25
Reach
40
